インビトロ毒物検査の世界市場：発癌性、経皮毒性、遺伝毒性、全身毒性、眼毒性、皮膚感作性、神経毒性、臓器毒性...市場調査レポートについてご紹介

1 Introduction (Page No. – 19)
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Segmentation
1.3.1 Years Considered in the Report
1.4 Currency
1.5 Limitations
1.6 Stakeholders

2 Research Methodology (Page No. – 23)
2.1 Market Size Estimation
2.2 Market Breakdown and Data Triangulation
2.3 Market Share Estimation
2.3.1 Key Data From Secondary Sources
2.3.2 Key Data From Primary Sources
2.3.3 Assumptions for the Study

3 Executive Summary (Page No. – 30)
3.1 Introduction
3.2 Current Scenario
3.3 Future Outlook
3.4 Conclusion

4 Premium Insights (Page No. – 39)
4.1 Global Market Overiew
4.2 Market: By Technology & Region
4.3 Market: Geographic Snapshot
4.4 Life Cycle Analysis, By Region (2016)

5 Market Overview (Page No. – 43)
5.1 Introduction
5.2 Market Segmentation
5.3 Market Dynamics
5.3.1 Drivers
5.3.1.1 Opposition to Animal Testing
5.3.1.2 New and Promising Technologies
5.3.1.3 Increasing R&D to Detect Toxicity at Early Stages
5.3.1.4 Insufficient Databases to Facilitate the Use of In Vitro Test Methods
5.3.2 Restraints
5.3.2.1 Predictive Ability of In Vitro Testing Leads to Decreasing Adoption of These Tests
5.3.2.2 Lack of In Vitro Models to Detect Autoimmunity & Immunostimulation
5.3.3 Opportunities
5.3.3.1 Growing Demand for In Vitro Toxicology in the European Market
5.3.3.2 Toxicology in the 21st Century (Tox21) Program
5.3.3.3 Increasing Drug Discovery and Innovation & Modernization in the In Vitro Toxicity Testing Market
5.3.4 Threat
5.3.4.1 Reluctance of Regulatory Authorities to Consider Alternate Methods for Proving Safety and Efficacy

6 Industry Insights (Page No. – 52)
6.1 Introduction
6.1.1 Increasing R&D Spending in Pharmaceutical and Biotechnology Sector
6.2 Key Focus Area
6.2.1 New and Promising Technological Advancements A Key Area of Focus for Market Players
6.3 Supply Chain Analysis
6.4 Porter’s Five Forces Analysis
6.4.1 Threat From New Entrants
6.4.2 Threat From Substitutes
6.4.3 Bargaining Power of Suppliers
6.4.4 Bargaining Power of Buyers
6.4.5 Intensity of Competitive Rivalry
6.5 Regulatory Committee Activities

7 In Vitro Toxicology Testing Market, By Product (Page No. – 59)
7.1 Introduction
7.2 Assays
7.2.1 Bacterial Toxicity Assays
7.2.2 Enzyme Toxicity Assays
7.2.3 Cell-Based Elisa and Western Blots
7.2.4 Receptor-Binding Assays
7.2.5 Tissue Culture Assays
7.2.6 Other Assays
7.3 Services
7.4 Reagents & Labware

8 In Vitro Toxicology Testing Market, By Type (Page No. – 77)
8.1 Introduction
8.2 ADME (Absorption, Distribution, Metabolism, and Excretion)
8.3 Dose
8.3.1 Dose Response
8.3.2 Threshold Response
8.4 Toxic Substance

9 In Vitro Toxicology Testing Market, By Toxicity Endpoints & Tests (Page No. – 88)
9.1 Introduction
9.2 Systemic Toxicity
9.3 Dermal Toxicity
9.4 Carcinogenicity
9.5 Ocular Toxicity
9.6 Skin Sensitization & Irritation
9.7 Genotoxicity
9.8 Neurotoxicity
9.9 Organ Toxicity
9.10 Other Toxicity Endpoints & Tests

10 In Vitro Toxicology Testing Market, By Technology (Page No. – 104)
10.1 Introduction
10.2 OMICS Technologies
10.2.1 Genomics
10.2.2 Proteomics
10.2.3 Metabolomics
10.2.4 Transcriptomics
10.2.5 Toxicogenomics
10.3 Cell Culture Technology
10.4 High-Throughput Technologies
10.5 Molecular Imaging Technologies

11 In Vitro Toxicology Testing Market, By Method (Page No. – 121)
11.1 Introduction
11.2 In Silico Methods
11.3 Biochemical Assays
11.4 Cellular Assays
11.5 Ex Vivo Models

12 In Vitro Toxicology Testing Market, By Industry (Page No. – 130)
12.1 Introduction
12.2 Cosmetics and Household Products
12.3 Diagnostics
12.3.1 Urine Screening
12.3.2 Alcohol Screening
12.3.3 Oral Fluid Screening
12.3.4 Hair Screening
12.3.5 Others
12.4 Pharmaceuticals
12.5 Food Industry
12.6 Chemicals

13 In Vitro Toxicology Testing Market, By Region (Page No. – 149)
13.1 Introduction
13.2 Europe
13.3 North America
13.3.1 U.S.
13.3.2 Canada
13.4 Asia
13.5 Rest of the World

14 Competitive Landscape (Page No. – 198)
14.1 Introduction
14.2 Strategic Analysis
14.3 Leading Players in the Market
14.4 Competitive Situation and Trends
14.4.1 New Product Launches and Product Upgrades
14.4.2 Acquisition
14.4.3 Agreements, Collaborations, and Partnerships
14.4.4 New Service Launch
14.4.5 Expansion
14.4.6 Other Developments

15 Company Profiles (Page No. – 208)
(Overview, Financial*, Products & Services, Strategy, and Developments)
15.1 Introduction
15.2 Agilent Technologies, Inc.
15.3 Covance
15.4 Bio-Rad Laboratories, Inc.
15.5 General Electric Company
15.6 Eurofins Scientific SE
15.7 Bioreliance, Inc. (A Subsidiary of Merck & Co, Inc.)
15.8 Thermo Fisher Scientific, Inc.
15.9 Charles River Laboratories International, Inc.
15.10 Catalent
15.11 Cyprotex

*Details Might Not Be Captured in Case of Unlisted Companies.

16 Appendix (Page No. – 245)
16.1 Insights of Industry Experts
16.2 Discussion Guide
16.3 Other Developments
16.4 Knowledge Store: Marketsandmarkets’ Subscription Portal
16.5 Introducing RT: Real-Time Market Intelligence
16.6 Available Customizations
16.7 Related Reports